PC 286

Drug Profile

PC 286

Latest Information Update: 15 Jun 2001

Price : $50

At a glance

  • Originator SSP Co
  • Class Antihypertensives; Small molecules
  • Mechanism of Action Potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Hypertension

Most Recent Events

  • 15 Jun 2001 Discontinued-Preclinical for Hypertension in Japan (PO)
  • 18 Nov 1998 No-Development-Reported for Hypertension in Japan (PO)
  • 23 Sep 1996 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top